Related references
Note: Only part of the references are listed.Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants
Amy E. Armstrong et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium
Frank M. Balis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Annette Kuenkele et al.
CLINICAL CANCER RESEARCH (2017)
Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients
K. C. J. M. Kraal et al.
EUROPEAN JOURNAL OF CANCER (2017)
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project
Mark A. Applebaum et al.
EUROPEAN JOURNAL OF CANCER (2017)
Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement
Matthew J. Ferris et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma
Daniel von Allmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma
Thomas Cash et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma
Anne Stone et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Chemoimmunotherapy for high-risk neuroblastoma
Brian H. Kushner
LANCET ONCOLOGY (2017)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2017)
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
J. Pan et al.
LEUKEMIA (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Valentina Boeva et al.
NATURE GENETICS (2017)
Proton beam therapy for olfactory neuroblastoma
Naoki Nakamura et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Lars M. Wagner et al.
ONCOTARGETS AND THERAPY (2017)
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Jiangtao Ren et al.
PROTEIN & CELL (2017)
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
Kevin Campbell et al.
CANCER (2017)
Assessment of Programmed Death-Ligand 1 Expression and Tumor-Associated Immune Cells in Pediatric Cancer Tissues
Robbie G. Majzner et al.
CANCER (2017)
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Ombretta Melaiu et al.
CLINICAL CANCER RESEARCH (2017)
Retinoblastoma and Neuroblastoma Predisposition and Surveillance
Junne Kamihara et al.
CLINICAL CANCER RESEARCH (2017)
Genetic susceptibility to neuroblastoma
Vanessa P. Tolbert et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2017)
Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients
C. Pasqualini et al.
BONE MARROW TRANSPLANTATION (2016)
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
Yael P. Mosse
CLINICAL CANCER RESEARCH (2016)
MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Tarek Shalaby et al.
CURRENT CANCER DRUG TARGETS (2016)
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers
Yasser Elborai et al.
PEDIATRIC TRANSPLANTATION (2016)
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin
Brian H. Kushner et al.
ONCOTARGET (2016)
PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance
Alessandra Dondero et al.
ONCOIMMUNOLOGY (2016)
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma
A. V. Desai et al.
BONE MARROW TRANSPLANTATION (2016)
The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis
Shuijie Li et al.
DEVELOPMENTAL CELL (2016)
Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors
Maja Olsson et al.
EPIGENETICS (2016)
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma
Christopher J. Forlenza et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan
Akiko Ioka et al.
JOURNAL OF EPIDEMIOLOGY (2016)
Neuroblastoma Mass Screening-What Can We Learn From It?
Kota Katanoda
JOURNAL OF EPIDEMIOLOGY (2016)
Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation Cochrane Review
F. Peinemann et al.
KLINISCHE PADIATRIE (2016)
Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma
John T. Powers et al.
NATURE (2016)
Can neoadjuvant chemotherapy reduce the surgical risks for localized neuroblastoma patients with image-defined risk factors at the time of diagnosis?
Akihiro Yoneda et al.
PEDIATRIC SURGERY INTERNATIONAL (2016)
Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies
Erika A. Newman et al.
SEMINARS IN PEDIATRIC SURGERY (2016)
Evidence-based paediatric surgical oncology
Paul D. Losty
SEMINARS IN PEDIATRIC SURGERY (2016)
Complications in the surgical management of children with malignant solid tumors
Andrew M. Davidoff et al.
SEMINARS IN PEDIATRIC SURGERY (2016)
CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases
Faheem Ahmed Khan et al.
ONCOTARGET (2016)
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression
Vito Alessandro Lasorsa et al.
ONCOTARGET (2016)
Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma
Shunpei Satoh et al.
SCIENTIFIC REPORTS (2016)
The impact of HLA Class I-Specific Killer Cell immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection
Raja Rajalingam
FRONTIERS IN IMMUNOLOGY (2016)
Neuroblastoma patients with high-affinity FCGR2A,-3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
Nikolai Siebert et al.
OncoImmunology (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells
Wataru Shoji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
Gregory A. Yanik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Local control in metastatic neuroblastoma in children over 1 year of age
Maria Antonietta De Ioris et al.
BMC CANCER (2015)
Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
S. G. DuBois et al.
BRITISH JOURNAL OF CANCER (2015)
Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma
Karin Melanie Cabanillas Stanchi et al.
CANCER BIOLOGY & THERAPY (2015)
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis
Robert W. Schnepp et al.
CANCER CELL (2015)
Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells
S. M. Rafiqul Islam et al.
CANCER SCIENCE (2015)
Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas
Yoshiki Kaneko et al.
CANCER SCIENCE (2015)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Validity of image-defined risk factors in localized neuroblastoma: A report from two centers in Western Japan
Shigehisa Fumino et al.
JOURNAL OF PEDIATRIC SURGERY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Martin Peifer et al.
NATURE (2015)
Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism
Derek A. Oldridge et al.
NATURE (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm et al.
NATURE GENETICS (2015)
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
Linda J. Valentijn et al.
NATURE GENETICS (2015)
Upfront Treatment of High-Risk Neuroblastoma With a Combination of 131I-MIBG and Topotecan
Kathelijne C. J. M. Kraal et al.
PEDIATRIC BLOOD & CANCER (2015)
Value of surgical resection in children with high-risk neuroblastoma
Brian R. Englum et al.
PEDIATRIC BLOOD & CANCER (2015)
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset
Karin Larsson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Daniel R. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
Daiki Kayano et al.
TheScientificWorldJOURNAL (2015)
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
Malvina Prapa et al.
ONCOTARGET (2015)
Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
Daiki Kayano et al.
Scientific World Journal (2015)
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study
Brian H. Kushner et al.
ONCOIMMUNOLOGY (2015)
Immunotherapy of childhood Sarcomas
Stephen S. Roberts et al.
FRONTIERS IN ONCOLOGY (2015)
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Andre Oberthuer et al.
CLINICAL CANCER RESEARCH (2015)
Prostaglandin E-2 promotes MYCN non-amplified neuroblastoma cell survival via beta-catenin stabilization
Sepp R. Jansen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Dexmedetomidine and Hydromorphone: A Novel Pain Management Strategy for the Oncology Ward Setting During Anti-GD2 Immunotherapy for High-Risk Neuroblastoma in Children
Matthias Goerges et al.
PEDIATRIC BLOOD & CANCER (2015)
Going Back to Class I: MHC and Immunotherapies for Childhood Cancer
Kellie B. Haworth et al.
PEDIATRIC BLOOD & CANCER (2015)
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
Bilgehan Yalcin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems
L. E. Cohen et al.
BONE MARROW TRANSPLANTATION (2014)
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
William Clay Gustafson et al.
CANCER CELL (2014)
The Risk-Associated Long Noncoding RNA NBAT-1 Controls Neuroblastoma Progression by Regulating Cell Proliferation and Neuronal Differentiation
Gaurav Kumar Pandey et al.
CANCER CELL (2014)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
Trim32 Facilitates Degradation of MYCN on Spindle Poles and Induces Asymmetric Cell Division in Human Neuroblastoma Cells
Hideki Izumi et al.
CANCER RESEARCH (2014)
High Expression of CAI2, a 9p21-Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma
Lisa M. Barnhill et al.
CANCER RESEARCH (2014)
Premature Termination of Reprogramming In Vivo Leads to Cancer Development through Altered Epigenetic Regulation
Kotaro Ohnishi et al.
CELL (2014)
Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
John Maher
CURRENT GENE THERAPY (2014)
Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma
Alexei L. Polishchuk et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: AEuropean HR-NBL1/SIOPEN Study
Virginie F. Viprey et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Acute Pain Relief After Mantram Meditation in Children With Neuroblastoma Undergoing Anti-GD2 Monoclonal Antibody Therapy
Mahiuddin Ahmed et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)
Long-Term Follow-Up Results of the Observation Program for Neuroblastoma Detected at 6-Month Mass Screening
Ayumu Arakawa et al.
JOURNAL OF PEDIATRICS (2014)
Rare Variants in TP53 and Susceptibility to Neuroblastoma
Sharon J. Diskin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Effects of a Novel Long Noncoding RNA, IncUSMycN, on N-Myc Expression and Neuroblastoma Progression
Pei Y. Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential
Himisha Beltran
MOLECULAR CANCER RESEARCH (2014)
Mechanisms of neuroblastoma regression
Garrett M. Brodeur et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
MicroRNAs in Neuroblastoma: Small-Sized Players with a Large Impact
Feng Zhi et al.
NEUROCHEMICAL RESEARCH (2014)
Does Aggressive Surgical Resection Improve Survival in Advanced Stage 3 and 4 Neuroblastoma? A Systematic Review and Meta-analysis
Dhanya Mullassery et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2014)
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling
Marie Will et al.
CANCER DISCOVERY (2014)
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
Nathan F. Moore et al.
ONCOTARGET (2014)
NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas
Yusuke Suenaga et al.
PLOS GENETICS (2014)
Symmetry breaking in human neuroblastoma cells
Hideki Izumi et al.
MOLECULAR & CELLULAR ONCOLOGY (2014)
Platinum compounds in children with cancer: toxicity and clinical management
Antonio Ruggiero et al.
ANTI-CANCER DRUGS (2013)
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience
G. A. Hale et al.
BONE MARROW TRANSPLANTATION (2013)
Ifosfamide, carboplatin, and etoposide for neuroblastoma
Brian H. Kushner et al.
CANCER (2013)
Neuroblastoma of Undifferentiated Subtype, Prognostic Significance of Prominent Nucleolar Formation, and MYC/MYCN Protein Expression
Larry L. Wang et al.
CANCER (2013)
Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma
Markus Brockmann et al.
CANCER CELL (2013)
Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma
Tasnim Ara et al.
CANCER RESEARCH (2013)
A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
Lia Gore et al.
CLINICAL CANCER RESEARCH (2013)
New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK
Giuseppe Barone et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study
J. A. Kohler et al.
EUROPEAN JOURNAL OF CANCER (2013)
Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
Gitta Bleeker et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Successful treatment of infants with localized neuroblastoma based on their MYCN status
Tomoko Iehara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression
Yuyan Zhu et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis
Thorsten Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ultrahigh-risk Group Within the High-risk Neuroblastoma Category
Ulla M. Saarinen-Pihkala et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
Susan G. Kreissman et al.
LANCET ONCOLOGY (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
Mark Sausen et al.
NATURE GENETICS (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Julie R. Park et al.
PEDIATRIC BLOOD & CANCER (2013)
Long-Term Follow-Up of the Thyroid Gland After Treatment With 131I-Metaiodobenzylguanidine in Children With Neuroblastoma: Importance of Continuous Surveillance
S. C. Clement et al.
PEDIATRIC BLOOD & CANCER (2013)
Proton versus photon radiation therapy for patients with high-risk neuroblastoma: The need for a customized approach
Christine Hill-Kayser et al.
PEDIATRIC BLOOD & CANCER (2013)
Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
Mike-Andrew Westhoff et al.
PLOS ONE (2013)
Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas
Hiroshi Fuji et al.
RADIATION ONCOLOGY (2013)
Clinical results of proton beam therapy for advanced neuroblastoma
Yoshiko Oshiro et al.
RADIATION ONCOLOGY (2013)
Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas
Naohiko Ikegaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
Md. Kamrul Hasan et al.
SCIENTIFIC REPORTS (2013)
Neuroblastoma and MYCN
Miller Huang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants A Children's Oncology Group Study
Jed G. Nuchtern et al.
ANNALS OF SURGERY (2012)
EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1, CLU, RUNX3, and NGFR
Chunxi Wang et al.
CANCER RESEARCH (2012)
1p36 Tumor Suppression-A Matter of Dosage?
Kai-Oliver Henrich et al.
CANCER RESEARCH (2012)
NLRR1 Enhances EGF-Mediated MYCN Induction in Neuroblastoma and Accelerates Tumor Growth In Vivo
Shamim Hossain et al.
CANCER RESEARCH (2012)
Mechanisms of CHD5 Inactivation in Neuroblastomas
Hiroshi Koyama et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2012)
Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma
Zhijie Li et al.
CLINICAL CANCER RESEARCH (2012)
Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma
Thorsten Simon et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2012)
Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience
Marion Strullu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Proton Radiotherapy for High-Risk Pediatric Neuroblastoma: Early Outcomes and Dose Comparison
Jona A. Hattangadi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Shahab Asgharzadeh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641
Douglas R. Strother et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
N-myc and Noncoding RNAs in Neuroblastoma
Jochen Buechner et al.
MOLECULAR CANCER RESEARCH (2012)
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Jan J. Molenaar et al.
NATURE (2012)
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Sharon J. Diskin et al.
NATURE GENETICS (2012)
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
Jan J. Molenaar et al.
NATURE GENETICS (2012)
Targeting ALK in neuroblastoma-preclinical and clinical advancements
Erica L. Carpenter et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group
Meaghan Granger et al.
PEDIATRIC BLOOD & CANCER (2012)
Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?
S. Zwaveling et al.
PEDIATRIC SURGERY INTERNATIONAL (2012)
Evidence of asymmetric cell division and centrosome inheritance in human neuroblastoma cells
Hideki Izumi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Yvan H. Chanthery et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Neonatal neuroblastoma
Jonathan P. H. Fisher et al.
SEMINARS IN FETAL & NEONATAL MEDICINE (2012)
Increasing the clinical efficacy of NK and antibody-mediated cancer imnnunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma
Tony A. Koehn et al.
FRONTIERS IN PHARMACOLOGY (2012)
Targeting Angiogenesis for Controlling Neuroblastoma
Subhasree Roy Choudhury et al.
JOURNAL OF ONCOLOGY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Thorsten Simon et al.
BMC CANCER (2011)
Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial
C. Jubert et al.
BONE MARROW TRANSPLANTATION (2011)
Oncogenic mutations of ALK in neuroblastoma
Seishi Ogawa et al.
CANCER SCIENCE (2011)
Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma
Jesmin Akter et al.
CLINICAL CANCER RESEARCH (2011)
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
S. J. Shuttleworth et al.
CURRENT MEDICINAL CHEMISTRY (2011)
ATP-Competitive Inhibitors of mTOR: An Update
S. Schenone et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma
Maria Antonietta De Ioris et al.
EUROPEAN JOURNAL OF CANCER (2011)
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas
Ruimin Huang et al.
FASEB JOURNAL (2011)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma
Giselle L. Saulnier Sholler et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma
Barrie S. Rich et al.
JOURNAL OF PEDIATRIC SURGERY (2011)
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Kai Wang et al.
NATURE (2011)
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours
Benjamin Beck et al.
NATURE (2011)
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis
A. Bender et al.
ONCOGENE (2011)
Oncogenic LMO3 Collaborates with HEN2 to Enhance Neuroblastoma Cell Growth through Transactivation of Mash1
Eriko Isogai et al.
PLOS ONE (2011)
Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project
Herve J. Brisse et al.
RADIOLOGY (2011)
Immunology and immunotherapy of neuroblastoma
Robert C. Seeger
SEMINARS IN CANCER BIOLOGY (2011)
T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
Pietro Sodani et al.
PEDIATRIC REPORTS (2011)
Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation
S. Ash et al.
BRITISH JOURNAL OF CANCER (2010)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado et al.
CANCER RESEARCH (2010)
Global genomic and RNA profiles for novel risk stratification of neuroblastoma
Miki Ohira et al.
CANCER SCIENCE (2010)
An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells
Manuele Castelnuovo et al.
FASEB JOURNAL (2010)
Accumulation of Segmental Alterations Determines Progression in Neuroblastoma
Gudrun Schleiermacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mortality and morbidity of patients with neuroblastoma who survived for more than 10 years after treatment-Niigata Tumor Board Study
Masayuki Kubota et al.
JOURNAL OF PEDIATRIC SURGERY (2010)
Asymmetric cell division: recent developments and their implications for tumour biology
Juergen A. Knoblich
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bβ and TSLC1 in neuroblastoma
H. Ochiai et al.
ONCOGENE (2010)
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset
Helena Caren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Tobias Otto et al.
CANCER CELL (2009)
Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD
Shifra Ash et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Inhibition of ALK Signaling for Cancer Therapy
Yael P. Mosse et al.
CLINICAL CANCER RESEARCH (2009)
KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma
Jeffrey M. Venstrom et al.
CLINICAL CANCER RESEARCH (2009)
Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma
Lizzia Raffaghello et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2009)
EXCELLENT LOCAL CONTROL FROM RADIATION THERAPY FOR HIGH-RISK NEUROBLASTOMA
Heather G. Gatcombe et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Isabelle Janoueix-Lerosey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience
Adela Canete et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification
Bruno De Bernardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Tom Monclair et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Secular Trends in Neuroblastoma Mortality Before and After the Cessation of National Mass Screening in Japan
Kota Katanoda et al.
JOURNAL OF EPIDEMIOLOGY (2009)
Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo
Giselle L. Saulnier Sholler et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Caroline Laverdiere et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Copy number variation at 1q21.1 associated with neuroblastoma
Sharon J. Diskin et al.
NATURE (2009)
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Mario Capasso et al.
NATURE GENETICS (2009)
KIR-HLA Receptor-Ligand Mismatch Associated With a Graft-Versus-Tumor Effect in Haploidentical Stem Cell Transplantation for Pediatric Metastatic Solid Tumors
Antonio Perez-Martinez et al.
PEDIATRIC BLOOD & CANCER (2009)
Outcome of High-Risk Stage 3 Neuroblastoma With Myeloablative Therapy and 13-cis-Retinoic Acid: A Report From the Children's Oncology Group
Julie R. Park et al.
PEDIATRIC BLOOD & CANCER (2009)
HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells
Alexander Pietras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
Daniel A. Mulrooney et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
28 years of high-dose therapy and SCT for neuroblastoma in Europe:: lessons from more than 4000 procedures
R. Ladenstein et al.
BONE MARROW TRANSPLANTATION (2008)
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
B. De Bernardi et al.
BRITISH JOURNAL OF CANCER (2008)
Hypoxia-inducible factor-2α transactivates Abcg2 and promotes cytoprotection in cardiac side population cells
Cindy M. Martin et al.
CIRCULATION RESEARCH (2008)
Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells
Danielle Boller et al.
CLINICAL CANCER RESEARCH (2008)
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age
Jan de Kraker et al.
EUROPEAN JOURNAL OF CANCER (2008)
The kinesin KIF1B beta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor
Susanne Schlisio et al.
GENES & DEVELOPMENT (2008)
Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation
Kiyohiro Ando et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
KIF1Bβ functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death
Arasambattu K. Munirajan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Rare occurrence of PHOX2b mutations in sporadic neuroblastomas
Alexandre Serra et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2008)
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
Tomoyuki Fujita et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study
Eiso Hiyama et al.
LANCET (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Mechanisms of asymmetric cell division:: flies and worms pave the way
Pierre Goenczy
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
John M. Maris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1(NLRR1) gene in neuroblastoma
M. S. Hossain et al.
ONCOGENE (2008)
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
E. H. Raabe et al.
ONCOGENE (2008)
Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature
N. Tomioka et al.
ONCOGENE (2008)
Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway
Zhijie Li et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: Report from the Children's Oncology Group
James G. Gurney et al.
PEDIATRICS (2007)
Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma
Amy M. Gillis et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
C. Welch et al.
ONCOGENE (2007)
Human neuroblastoma stem cells
Robert A. Ross et al.
SEMINARS IN CANCER BIOLOGY (2007)
Spindle orientation, asymmetric division and tumour suppression in Drosophila stem cells
Cayetano Gonzalez
NATURE REVIEWS GENETICS (2007)
Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation
Anders Edsjo et al.
SEMINARS IN CANCER BIOLOGY (2007)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CHD5 is a tumor suppressor at human 1p36
Anindya Bagchi et al.
CELL (2007)
Activation of Akt predicts poor outcome in neuroblastoma
Daniela Opel et al.
CANCER RESEARCH (2007)
Bmi-1 is essential for the tumorigenicity of neuroblastoma cells
Hongjuan Cui et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma:: HIF-2α promotes an aggressive phenotype
Linda Holmquist-Mengelbier et al.
CANCER CELL (2006)
Antitumor activity of nifurtimox observed in a patient with neuroblastoma
Giselle L. Saulnier Sholler et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
Louis Chesler et al.
CANCER RESEARCH (2006)
Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease
Thorsten Simon et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2006)
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update
RE George et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
T. Iehara et al.
BRITISH JOURNAL OF CANCER (2006)
Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas
T Machida et al.
ONCOGENE (2006)
HIF-2α regulates Oct-4:: effects of hypoxia on stem cell function, embryonic development, and tumor growth
KL Covello et al.
GENES & DEVELOPMENT (2006)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas
K Nowak et al.
NUCLEIC ACIDS RESEARCH (2006)
Long-term outcomes of adult survivors of childhood cancer - Results from the childhood cancer survivor study
LL Robison et al.
CANCER (2005)
Chromosome 1p and 11q deletions and outcome in neuroblastoma
EF Attiyeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidural compression in neuroblastoma:: Diagnostic and therapeutic aspects
B De Bernardi et al.
CANCER LETTERS (2005)
Phox2B mutations and the Delta-Notch pathway in neuroblastoma
V van Limpt et al.
CANCER LETTERS (2005)
Ovarian function following pelvic irradiation in prepubertal and pubertal girls and young adult women
A Schuck et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOPNBL90 study
C Bergeron et al.
PEDIATRIC BLOOD & CANCER (2005)
Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant
D von Allmen et al.
JOURNAL OF PEDIATRIC SURGERY (2005)
LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma
M Aoyama et al.
CANCER RESEARCH (2005)
High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group
J Pritchard et al.
PEDIATRIC BLOOD & CANCER (2005)
Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study
T Oue et al.
JOURNAL OF PEDIATRIC SURGERY (2005)
Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma
CC Koh et al.
PEDIATRIC SURGERY INTERNATIONAL (2005)
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma
D Trochet et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
The impact of gross total resection on local control and survival in high-risk neuroblastoma
MP La Quaglia et al.
JOURNAL OF PEDIATRIC SURGERY (2004)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Long-term follow-up status of patients with neuroblastoma after undergoing either aggressive surgery or chemotherapy - A single institutional study
M Kubota et al.
JOURNAL OF PEDIATRIC SURGERY (2004)
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma
M Alaminos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The Phox2B homeobox gene is mutated in sporadic neuroblastomas
V van Limpt et al.
ONCOGENE (2004)
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
SG DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A systematic review of molecular and biological tumor markers in neuroblastoma
RD Riley et al.
CLINICAL CANCER RESEARCH (2004)
Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study
ES Adkins et al.
JOURNAL OF PEDIATRIC SURGERY (2004)
Germline PHOX2B mutation in hereditary neuroblastoma
YP Mosse et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Revision of the international neuroblastoma pathology classification - Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular
M Peuchmaur et al.
CANCER (2003)
Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome
J Amiel et al.
NATURE GENETICS (2003)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants
KJ Marcus et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
The role of surgery in stage IV neuroblastoma
V Castel et al.
JOURNAL OF PEDIATRIC SURGERY (2002)
Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification
M Kaneko et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype
A Jögi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma
GA Yanik et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Neuroblastoma screening at one year of age
FH Schilling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Locoregional control in infants with neuroblastoma: Role of radiation therapy and late toxicity
AC Paulino et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Late mortality experience in five-year survivors of childhood and adolescent cancer: The childhood cancer survivor study
AC Mertens et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
HJ Nickerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study
CA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Local control with multimodality therapy for stage 4 neuroblastoma
SL Wolden et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Share Paper
